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Background. Liver allografts are accepted across 
major histocompatibility complex (MIlC) barriers in 
mice and induce donor-specific tolerance without re-
quirement for immunosuppressive therapy. There is 
evidence that passenger leukocytes may play a key 
role in tolerance induction. FIt-3 ligand (FL) is are-
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cently cloned hematopoietic cytokine that strikingly 
augments functional dendritic cells (DCs) within lym-
phoid and nonlymphoid tissue. 
Methods. The expression of costimulatory molecules 
and MIIC class II antigen on DCs isolated from livers 
of FL-treated BIO (H2b ) mice (10 Ilglday; 10 days) was 
examined by flow cytometric analysis, and their allo 
stimulatory activity assessed in primary mixed leuko 
cyte cultures. BI0 livers from FL-treated donors were 
transplanted orthotopically into naive C3H (H2k) re-
cipients. Donor cells (MIle class 11+) in recipient 
spleens were identified by immunohistochemistry. 
Antidonor cytotoxic T lymphocyte activity, and both 
natural killer and lymphokine-activated killer cell ac-
tivities of graft nonparenchymal cells and host spleno-
cytes were determined using isotope release assays. 
Apoptotic activity within liver grafts was determined 
by terminal deoxynucleotidyltransferase-mediated 
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dUTP-biotin nick end labeling. 
Results. DCs isolated from livers of FL-treated donor 
mice exhibited increased cell surface expression of 
CD40, CD80, CD86, and lAb, and augmented T cell al-
lostimulatory activity compared with controls. Within 
24 hr of organ transplantation, the numbers of donor 
IAb + cells within recipient spleens was augmented 
substantially compared with normal liver recipients. 
Livers from FL-treated donors were rejected acutely 
(median survival time, 5 days), whereas control BI0 
liver allografts survived > 100 days. Nonparenchymal 
cells from rejecting grafts 4 days after transplantation 
exhibited increased antidonor cytotoxic T lympho-
cyte, natural killer, and lymphokine-activated killer 
cell activities compared with cells from spontaneously 
accepted grafts. This augmented cytotoxic reactivity 
was associated with histologic evidence of injury to 
bile duct epithelium and vascular endothelium that 
was not readily evident in controls. 
Conclusion.. Thus, although normal livers provide 
allostimulatory signals sufficient to elicit an antido-
nor immune response, regulatory mechanisms that 
may include apoptosis of graft-infiltrating T cells, and 
that are overcome by augmenting the number of func-
tional donor DCs, may account for inherent liver 
tolerogenicity. 
In most mouse and certain rat strain combinations, liver 
allografts are accepted across major histocompatibility com-
plex (MHC*) barriers, and induce donor-specific tolerance, 
without the need for immunosuppressive therapy (1). Why 
this occurs frequently with the liver (and only exceptionally 
for mouse heart or kidney) is poorly understood. Mechanisms 
suggested to account for liver tolerogenicity (reviewed in 2 
and 3) include low constitutive MHC antigen expression by 
hepatocytes, immunoregulatory effects of soluble hepatocyte 
products or donor MHC class I antigens, "insufficiency" of T 
helper-l cell cytokines (4), "tolerogenic" donor-derived anti-
gen-presenting cells (APCs) (5), and contrastingly, "superin-
duction" of T cell responses (resulting in proliferative clonal 
exhaustion and deletion; 6). There is evidence that "passen-
ger" leukocytes may play a key role in determining the out-
come of allogeneic liver transplantation. Compared with the 
heart or kidney, the liver is comparatively rich in interstitial 
leukocytes, including APCs, and in particular, dendritic cells 
(DCs) (7, 8). Persistence of multiline age donor-derived leuko-
cytes, including DC progenitors, in recipient tissues is asso-
ciated with liver transplant tolerance (1, 5, 9-12). Moreover, 
in spontaneous liver acceptance models, depletion of passen-
ger leukocytes from the donor organ results in allograft re-
jection (13). We have suggested recently (14) that apoptosis of 
alloactivated T cells infiltrating liver portal areas (that are 
rich in DCs; 8) may be a mechanism underlying liver trans-
phmt tolerance. 
DCs represent only a small proportion of the interstitial 
leukocytes within normal tissue (15). Unlike DCs resident 
within lymphoid tissue such as spleen, freshly isolated MHC 
• Abbreviations: APC, antigen-presenting cell; BM, bone marrow; 
CTL, cytotoxic T lymphocyte; DC, dendritic cell; FL, FIt-3 ligand; IL, 
interleukin; LAK, lymphokine-activated killer; MHC, major histo-
compatibility complex; NPC, non parenchymal cell; NK, natural kill-
er; PBS, phosphate-buffered saline; RT, room temperature; TdT, 
terminal deoxynucieotidyltransferase; TUNEL, TdT-mediated 
dUTP-biotin nick end labeling. 
class n+ DCs from nonlymphoid organs are poor allostimu-
lators (16, 17). This is consistent with the apparent lack of 
invariant chain (18), and low or absent costimulatory mole-
cule expression (19) that suggests these nonlymphoid tissue 
DCs may have tolerogenic properties. Indeed, DC progenitors 
propagated from normal liver and administered systemically 
can prolong allograft survival in mice (20). Other evidence 
points to potential tolerogenicity of DCs (21-24). These and 
other findings (2, 5) indicate that liver tolerogenicity may 
reflect quantitative and/or qualitative deficiencies in the ca-
pacity of the donor APC population, in particular DCs, to 
elicit an effective immune response. 
FIt-3 ligand (FL) is a recently cloned hematopoietic growth 
factor (25), the cognate ligand of FIt-3, a receptor-type III 
tyrosine kinase (26) that is expressed on CD34 + stem cells. 
FL administration is highly effective in mobilizing stem and 
progenitor cells in vivo (27) and results in their accumulation 
in tissues. Unlike granulocyte-macrophage colony-stimulat-
ing factor, the essential myeloid DC growth factor in vitro, FL 
dramatically and selectively increases the number of nmc-
tional DCs in mouse lymphoid and nonlymphoid tissues (28). 
Recently, we reported that increasing the number of liver 
passenger leukocytes (in particular, the proportion of poten-
tial allostimulatory DCs) by donor pretreatment with FL 
prevented the induction of liver transplant tolerance (29). We 
now show that augmentation of functional donor DCs in this 
passenger leukocyte population is associated with large in-
creases in the number of donor-derived APCs within recipi-
ent lymphoid tissue, and with augmentation of antidonor 
cytotoxic T lymphocyte (CTL), natural killer (NK), and lym-
phokine-activated killer (LAK) cell activities of graft-infil-
trating cells. Transplantation of livers from FL-treated do-
nors was also associated with an altered pattern of in situ 
apoptotic activity. Thus, rather than inducing high dose un-
responsiveness, a large increase in delivery/presentation of 
donor alloantigen can overcome tolerance-inducing mecha-
nisms, and promote the expression of immune effector mech-
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FIGURE 1. Flow cytometric analysis of overnight (18 hr)-cultured, 
metrizamide-purified nonadherent cells isolated from the NPC pop-
ulation of FL-treated and control BID mouse livers. The results are 
representative of two separate experiments. 
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anisms consistent with bile duct and vascular cell injury 
leading to acute liver rejection. 
MATERIALS AND METHODS 
Animals. Male C57BU1OJ (B10; H2b, lAb, IE-) and C3H/HeJ 
(C3H; H2k, IEk, IAk) mice, 8-12 weeks of age, were purchased from 
The Jackson Laboratory, Bar Harbor, ME. 
FL treatment. Recombinant human FL derived from Chinese 
hamster ovary cells (28) (lmmunex Research and Development 
Corp., Seattle, WA; 10 ILg in 200 ILl of sterile Hanks' balanced salt 
solution) was given by daily intraperitoneal injection for 10 days. 
Control animals received Hanks' balanced salt solution (200 !J.l), 
using an identical regimen. Organs were harvested for analysis 
18-24 hr after the last treatment. 
Liver nonparenchymal cell (NPC) isolation and DC culture. Liv-
ers from FL-treated or control mice, or liver allografts were pooled 
(three to five animals per experiment). NPCs were isolated by colla-
genase digestion, followed by Percoll centrifugation (30). The NPCs 
comprised predominantly CD45+ leukocytes (at least 95% in both 
control and FL-treated animals). Metrizamide-purified DC prepara-
tions were obtained by overnight (18 hr) culture of liver Npr i, 
followed by centrifugation of the nonadherent cells over metrizam ;e 
(14.5% w/v, Sigma Chemical, St. Louis, MO), as described (8). 
Immunophenotypic analysis of cell suspensions. Immunofluores-
cence staining of cell-surface antigens for flow cytometric analysis, 
including double-labeling to identify the origin of the cells, was 
performed as described previously (30), using monoclonal antibodies 
purchased from PharMingen (San Diego, CAl. CDllc and DEC-205 
A MUCOassII 
Fluorescence intensity 
FIGURE 2. (A), Expression of MHC class II (lAb) on DCs isolated from livers of control (pale shading) and FL-treated mouse donors (dark 
shading); (B). DEC 205 (DC marker) and (C), MHC class II (lAb) expression on cytospin preparations ofmetrizamide-purified DCs isolated 
from the NPC population of FL-treated mouse livers. (Avidin-biotin-peroxidase stain; original magnification, X400.) 
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FIGURE 3. Expression of costimulatory molecules on overnight (18 
'hr) cultured, metrizamide-purified nonadherent cells isolated from 
the NPC population of normal (pale shading) or FL-treated mouse 
livers (dark shading). The results are representative of two separate 
experiments. 
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FIGURE 4. Allostimulatory activity for naive C3H splenic T cells of 
Des isolated from the livers of control and FL-treated BID mice. The 
mixed leukocyte reaction cultures were maintained for 72 hr. The 
8timulatory activity of freshly isolated bulk allogeneic (B1O) and 
syngeneic spleen cells is also shown. The results are means:!:SD of 
triplicate cultures. 
anti~ens were detected using hybridoma N418 (31) and NLDC-145 
(32) monoclonal antibody supernatants, respectively, that were pro-
vided by Dr. R.M. Steinman (Rockefeller University, New York, NY). 
Appropriate rat, hamster, or mouse Ig isotype controls were included 
in each experiment. Flow cytometric analysis was performed using a 
EPICS Elite flow cytometer (Coulter Corp., Hialeah, FL). Five thou-
land events were acquired for each sample. Cytocentrifuge prepara-
tions were stained with Giemsa or by immunocytochemistry (30, 33). 
Allostimulatory activity. One-way mixed leukocyte reaction cul-
tures were established in 96-well round-bottom microculture plates. 
Graded doses of r-irradiated (20 Gy; x-ray source) syngeneic or 
allogeneic (BID) stimulator cells were added to 2xlO" nylon wool-
eluted C3H spleen cells (8) used as responders. Cultures were main-
TABLE 1. Donor pretreatment with FL prevents "spontaneous" 
liver transplant tolerancea 
Donor treatment Survival Median n (days) survival time 
Control 5 >100 (X5) >100 
FU (10 /Lg/day) X 10 5 4,4,5,5,6 5 
days 
a Strain combination B10 (H2b ) ~ C3H (H2k ). 
EL-4 YAC-1 P815 
Liver NPC 
Spleen cells 
E:T ratio 
-0- C3H 
--r- B1rhC3H 
---cr B1Q->C3H flt3L 
FIGURE 5. CTL, NK, and LAK cell activities (specific 51Cr release) of 
FL-treated donor liver graft-infiltrating cells and host spleen cells 
against EL-4, YAC-1, and P815 target cells, respectively, 4 days after 
transplant. The results are representative of two separate experi-
ments. 
tained for 72 hr; [3Hlthymidine (1 /LCi/well) was added for the final 
18 hr, and incorporation of [3H]thymidine into DNA was assessed by 
liquid scintillation counting. Results were expressed as mean counts 
per minute (cpm) :!:lSD. 
Organ transplantation. Orthotopic liver transplantation was per-
formed from either FL-treated or control BID donors to C3H recipi-
ents, as described (34). No immunosuppressive therapy was given. 
Rejection was confirmed histologically. 
Immunohistology. Staining for donor MHC class II+ (IAb +) cells 
in cryostat sections of recipient spleens was performed as described 
previously in detail (30). 
CTL assays. Freshly isolated liver NPCs or spleen cells from 
either allograft recipients or control C3H mice were used as effectors 
at various effector-to-target cell ratios. The EL4 (H2b ) lymphoma cell 
line (TIB39; American Type Culture Collection [ATCC), Rockville, 
MD) was used as a source of donor-specific target cells (ATCC) in 
4-hr 51Cr release assays, as described (14). The percent specific 
cytotoxicity was calculated using the following formula: % cytotoxic-
ity = 100 x [experimental (cpm) - spontaneous (cpm)lmaximum 
(cpm) - spontaneous (cpm)l. Results are expressed as means :!:lSD 
of percent specific 51Cr release in triplicate cultures. 
Quantitation of NK and LAX cell activities. Lysis of YAC-1 tumor 
cells detected by 4-hr 51Cr release assay was used as an indicator of 
NK cell activity, whereas LAK cell activity and cytotoxicity towards 
third-party targets was determined by lysis of NK-resistant 51Cr_ 
labeled P-8l5 (H2d ) tumor cells (ATCC) (35). The tumor cell lines 
were grown in RPMI-1640 complete medium (Life Technologies, 
Gaithersburg, MD) and were subcultured two to three times per 
week. 
In situ detection of apoptotic cells in liver sections. Diced samples 
of freshly isolated liver were placed in embedding medium (Tissue-
Tek O.C.T. Compound; Miles Inc., Elkhart, IN). The tissue was 
snap-frozen in liquid nitrogen, and stored at -70·C until sectioned. 
Cryosections (4 /Lm) were mounted on precleaned slides, air-dried 
overnight at room temperature (RT). then fixed for 10 min at RT in 
1594 TRANSPLANTATION Vol. 65, No. 12 f 
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neutral buffered formaldehyde (pH 7.4), followed by two washes 
"JOin each) in phosphate-buffered saline (PBS). DNA strand breaks 
.r.re identified by in situ terminal deoxynucleotidyltransferase 
'D'dT)-mediated dUTP-biotin nick end labeling (TUNEL), as de-
;cn'bed (36), with some modifications. Sections were immersed in 2% 
k.02 in PBS for 5 min at RT to quench endogenous peroxidase 
j:tivity. then incubated with 20 /kg/ml proteinase K (Sigma) for 15 
lain at RT, washed in PBS, and immersed in reaction buffer supple-
_ted with TdT and biotinylated dUTP. Sections were incubated in 
a humid atmosphere at 37°C for 60 min. Each experiment was 
~prformed with a negative (without biotinylated dUTP) and a posi-
Jtve control (10 min pretreatment of sections with 1 mg/ml DNase 
'JtiIsolved in reaction buffer). Irradiated (5 Gy) thymocytes incubated JIr 18 hr and then cytocentrifuged onto glass slides (>90% apoptotic 
:i*lJs) also served as positive controls. After washing in stop/wash 
"lUft'er (30 min at 37°C), antidigoxigenin-peroxidase (Dncor, Gaith-
~burgI MD) was added (30 min at RT). The sections were washed in 
" , and the reaction developed with 3-amino-5-ethycarbizol. Slides 
counterstained with Harris' hematoxylin and mounted with 
tal mount (Biomeda Corp., Foster City, CAl. 
tatistical analyses. Statistical analyses were performed using 
ent's t test or the Mann-Whitney U test, as appropriate. 
RESULTS 
'Markedly increased numbers of allostimulatory DCs can be 
ted from liver NPCs of FL-treated mice. As reported 
'ously (29), there was a large increase in the absolute 
ber of liver leukocytes (NPCs) in FL-treated animals, 
uding a substantia130-50-fold increase, compared to con-
ls, in cells bearing the myeloid markers, Gr-1 and MAC-1 
, llb). There was also a large increase both in the relative 
absolute numbers of cells that were positive for the 
-restricted antigens, CDllc or DEC 205 (data not shown). 
i;:vestigate the liver DCs, highly purified preparations 
" "'" obtained after overnight (18 hr) culture of NPCs, and 
;,:elntrifugation of nonadherent cells over metrizamide. Com-
·:t'1'1' Ii" to control animals, from which only approximately , ", 10" DCs could be harvested per liver, about 6x 106 DCs 
.' ,," d be recovered from livers of 10-day FL-treated mice. The 
'. displayed morphologic and surface phenotypic features 
acteristic of DCs (Fig. 1), and were DEC 205+, F4J80-, 
Ohi, CD80+, CD86h\ and MHC class II (IAb)hi. The extent 
. lymphocyte contamination was very low. Significantly, an 
j 'tional3x106 DCs/liver could be harvested after a second 
of culture of cells from FL-treated mice in the absence of 
ulocyte-macrophage colony-stimulating factor. Adeli-
a! flow cytometric and immunocytochemical analyses in-
" , ted that overnight-cultured DCs from NPCs of both con-
KI~KDID"K ,,' I and FL-treated mouse livers expressed similar levels of 
." C class II (lAb) (Fig. 2), but that higher levels of CD40, 
'. 80 and CD86 were expressed on DCs from FL-treated 
!jmce (Fig. 3). This suggested that the DC population present 
'Ia FL-t n~ated livers was in a later stage of phenotypic mat-
. tion than that in controls. Consistent with their higher 
levels of expression of costimulatory molecules, DCs from 
FL-treated livers exhibited significantly increased allostimu-
latory activity for naive T cells compared to DCs from con-
trols (Fig. 4). 
FL treatment of organ donors results in acute liver allograft 
rejection. In the B10 to C3H strain combination, orthotopic 
liver allografts are accepted spontaneously in nonimmuno-
suppressed recipients. Treatment of liver donors with FL for 
10 days, however, resulted in the acute rejection of livers in 
all allograft recipients (median survival time, 5 days) (Table 
1). Liver allograft rejection was confirmed histologically. 
Increased donor MHC class IJ+ cells are observed in 
spleens of recipients of livers from FL-treated donors. Immu-
nohistochemical staining of spleens from recipients of hepatic 
allografts 24 hr after transplant revealed substantial in-
creases in donor MHC class 11+ (IAb+) cells in those mice 
given livers from FL-treated donors compared with controls 
(data not shown). 
FL pretreatment of liver donors augments CTL, NK, and 
LAK cell activities of graft-infiltrating cells. Similar numbers 
of graft-infiltrating cells with comparable immunophenotypic 
characteristics were isolated from the transplanted livers of 
control and FL-treated donors. By day 4 after transplant, 
>80% of these cells expressed recipient MHC class I pheno-
type (H2Kk ); of these, approximately 25% were CD4 + and 
30% CD8 +. It has been shown previously that freshly iso-
lated graft-infiltrating cells of normal liver allografts exhibit 
ex vivo antidonor CTL activity for a short period after trans-
plantation (14). This activity gradually subsides to normal 
levels as the grafts are accepted permanently. To test the 
antidonor responses of graft-infiltrating cells within livers 
from FL-treated donors, CTL, NK, and LAK cell activities 
were evaluated 4 days after transplantation. As shown in 
Figure 5, there were increases in all three activities when 
compared with those exhibited by cells isolated from control 
liver allografts. Corresponding activities of host spleen cells 
were also evaluated. There was increased antidonor CTL 
activity of spleen cells from mice given livers from FL-treated 
donors compared with the modest activity of control liver 
recipients' splenocytes. However, no alteration in the low NK 
and LAK cell activities of corresponding host spleen cells was 
observed. 
Increased bile duct and hepatocellular injury in liver grafts 
from FL-treated donors. Liver grafts harvested from experi-
mental and control animals were examined histologically 4 
days after transplantation. As reported previously (1), there 
was little evidence of damage to bile duct epithelium, hepa-
tocytes or vascular endothelial cells in control liver grafts, 
despite a prominent (mainly periportaVperivascular) inflam-
matory cell infiltrate. In contrast, liver grafts from FL-
treated donors, examined at the same time after transplant, 
exhibited an extensive, generalized mononuclear cell intil-
6. (A-DJ Histological appearance ofFL-treated B10 donor liver allografts 4 days after transplantation into normal C3H recipients. 
and B) normal liver allograft, showing predominantly periportal inflammation (Al, with absence of damage to bile duct epithelium (Bl. (C 
L_ D) FL-treated donor liver allograft, showing diffuse periportal and lobular inflammatory cell infiltration, with focal bile duct injury 
;~~eadsF and evidence of endothelial cell separation from a portal vein (arrow). (Hematoxylin and eosin stain; A and C, original 
:~cationI xlOO; B and D, original magnification, x200.) (E-H) TUNEL staining for apoptotic cells in liver allografts, 4 days after I~plantationK (E and F) normal liver allograft, showing apoptotic cells within the periportal inflammatory cell infiltrate (compare with A). 
tGand H) FL-treated donor liver allograft, showing larger, TUNEL-positive cells (presumptive apoptotic hepatocytes) throughout the lobular 
II~ (Counterstained with hematoxylin; E and G, original magnification, x 100; F and H, original magnification, X400.) 
<i' 
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trate, with clear evidence of bile duct damage, and vascular 
endothelial cell injury (Fig. 6, A-D). These findings were 
consistent with acute liver rejection (median survival time, 5 
days) in recipients of grafts from FL-treated donors. 
Apoptotic activity of liver parenchymal cells is enhanced 
and that of inflammatory cells decreased in liver grafts from 
FL-treated donors. It has been shown recently that sponta-
neous liver allograft acceptance in mice is associated with a 
relatively high incidence of apoptotic cells within the peri-
portal inflammatory cell infiltrate, that may be linked to 
deletion of donor-reactive CTL (14). In view of these obser-
vations, we compared apoptotic activity in allografts from 
FL-treated donors with those from control liver grafts, using 
the TUNEL assay for in situ DNA fragmentation. As shown 
in Figure 6 (E-H), there was a striking increase in the num-
ber of large apoptotic cells (presumed hepatocytes) through-
out the parenchyma of livers from FL-treated donor com-
pared with control liver grafts. The differential increase in 
apoptotic death of parenchymal cells was associated with a 
reduced incidence of TUNEL-positive inflammatory cells. 
This was consistent with the elevated levels of antidonor CTL 
activity of freshly isolated graft-infiltrating cells, and with 
increased numbers of inflammatory cells throughout the 
liver lobules compared with controls. 
DISCUSSION 
The present study describes a model of mouse liver allo-
graft rejection that is dependent on donor pretreatment with 
the potent hematopoietic growth factor FL. Rejection is as-
sociated with: (i) dramatic increases in the numbers of po-
tential allostimulatory DCs that can be recovered from the 
donor organ using conventional DC isolation procedures; (ii) 
substantial increases in donor MHC class IP cells within 
recipient lymphoid tissue 24 hr after transplant; (iii) poten-
tiation of antidonor CTL, NK, and LAK cell activities within 
the graft; and (iv) reduced apoptotic activity of graft-infiltrat-
ing cells. In virtually all H2-incompatible normal mouse 
strain combinations, liver transplant tolerance is achieved 
without the need for host immunosuppression (1). In con-
trast, skin allografts in the same combinations are rejected 
acutely. The mechanisms underlying "spontaneous" liver ac-
ceptance are poorly understood (2, 3). Liver acceptance oc-
curs despite early intragraft mononuclear leukocyte infiltra-
tion (1), that appears identical histologically to that observed 
in organ rejection, and that may reflect the "active" nature of 
liver-induced tolerance. Indeed, it has been suggested that, 
because liver tolerance in rats can be inhibited by steroid 
administration for the first 2 days after transplant, immune 
activation is key to the induction of donor-specific unrespon-
siveness (6). With the acceptance of liver allografts, the re-
cipients become permanently tolerant to donor-type chal-
lenge grafts, such as those of heart and even skin, indicating 
the robust nature of the tolerance (1, 38, 39). The process of 
tolerance induction can be prevented, however, by presensi-
tization of the liver recipient to donor alloantigens, usually 
by skin grafting 2 weeks or more before organ transplanta-
tion (40). With recipient presensitization, the liver is rejected 
acutely (within 4-5 days). Mouse liver allograft rejection also 
results from recipient treatment with recombinant mouse 
interleukin (lL)-2 (14) or IL-12 (4]), 
In recipients of normal liver allografts, graft NPCs isolated 
during the first week after transplant exhibit strong, donor-
specific CTL responses. This "paradoxical" CTL activity, de-
tected using donor MHC-positive cells as targets, correlates 
well with the extent of the histologic infiltrate that peak; 
between days 4 and 7, then diminishes rapidly and progre 
sively to normal levels. Despite these findings, there is litt . 
evidence of either bile duct or hepatocyte injury in the norm,,] 
mouse liver allograft recipient. Taken together, these obser-
vations suggest that, although donor-specific immunity is 
induced initially, it wanes rapidly as a result of the elimina-
tion of donor-specific CTL within the graft. Apoptosis of 
graft-infiltrating cells (14) by mechanisms yet to be eluci-
dated may play a key role in the process. It is conceivable 
that donor liver-derived NPCs or DCs (that may express Fas 
ligand [CD95L]) (42) could playa key role in the apoptosis of 
recipient activated T cells. The capacity of exogenous IL-2 to 
induce normal liver allograft rejection (41) may reflect pro-
tection of graft-infiltrating T cells from apoptosis (14). By 
contrast, the results of the present study show that dramatic 
increases in donor leukocytes, in particular functional DC 
leads to augmented early antidonor CTL activity of liv. 
graft-infiltrating cells, hepatocellular destruction, and all(,-
graft rejection. The observed increase in apoptosis of paren-
chymal cells is most likely due, predominantly, if not exclu-
sively, to the cytotoxic activity of host immune effector cells. 
The stimulus provided to unmodified hosts by substantially 
increased numbers of immunostimulatory donor DCs and 
probably other APCs is sufficient to overcome other mecha-
nisms that generally contribute to the success of liver allo-
grafts. 
As reported previously (29), treatment with FL for 10 days 
resulted in a dramatic accumulation of myelomonocytic cells 
within the liver, both in portal areas (where DCs are nor-
mally found; 8), and throughout the parenchyma. Augmen-
tation of the number of myeloid lineage cells far exceed( I 
that of lymphocytes, although these too were increased si. 
nificantly in absolute numbers. The largest increase (> 10U-
fold) was observed in the absolute number of cells bearing the 
DC-restricted cell surface antigenic markers DEC-205 or 
CDllc. The most striking evidence of the large increase in 
DCs within FL-treated mouse livers was, however, the huge 
increase in the absolute number ofCDllc+ cells that could be 
recovered after overnight culture of liver NPCs. Evidence 
that these cultured cells had rapidly undergone functional 
maturation was provided by the high levels of surface MHC 
class II, CD40, CDSO, and CDS6, and their potent allostimu-
latory capacity. These findings are consistent with recent 
reports that FL may preferentially mobilize or enhance the 
development of myeloid (28, 29) or myelomonocytic linea! ' 
cells (43), and also enhance DC accumulation in mouse t 
sues (28). This in tum, may be associated with increasi i 
levels of secreted IL-12 and/or other cytokines/growth factor:; 
that promote graft immunogenicity, and possibly, DC prolif-
eration. DC-derived IL-12 could augment CD4 + Thl cell re-
sponses that have been linked previously to murine liver 
allograft rejection (4, 41). Although not examined in the 
present study, it is conceivable that a component of the 
multilineage NPC accumulation within the liver is derived 
from local lineage-committed progenitor cell proliferation 
and maturation (30). This could also be achieved through 
S 
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proliferation of stem cells in the liver (44, 45) induced or 
enhanced by FL administration. 
As shown previously, both in mouse and rat models, sys-
temic effects of normal liver transplantation include the ca-
pacity of liver leukocytes (including progenitor and stem 
cells) (1, 5, 46, 47), to migrate extensively to recipient lym-
phoid and nonlymphoid tissues, where they may persist in-
definitely. These donor-derived cells may provide not only a 
continuing source of allostimulation, but may also have the 
capacity to modulate the survival and function of alloacti-
vated T cells within the recipient lymphoid system (10, 48, 
49). Key molecules that may be expressed by donor-derived 
Des, including costimulatory molecules (22, 42), inducible 
nitric oxide synthase (37), and Fas ligand (42) could play 
important regulatory roles in these cell interactions. Re-
cently, emphasis has been placed on multilineage donor he-
matolymphopoietic cell chimerism as the basis for organ al-
lograft acceptance (9, 48, 49). Although tolerance and 
chimerism are spontaneous in the mouse liver transplant 
model (1, 2), they require an umbrella of immunosuppression 
in most models (including human organ transplantation) to 
prevent one of the interacting donor and recipient immune 
populations from overwhelming the other (50). With an un-
controlled imbalance, the result is rejection or graft-versus-
host disease (51). It has been emphasized as a therapeutic 
principle, that attempts to augment donor chimerism clini-
cally with either adjunct donor leukocytes (i.e., bone marrow 
[BM] cells) or by administration of hematolymphopoietic 
growth factors, is predictably unsafe, unless it is done under 
immune suppression that affects both cell populations 
equally (49). The present study reinforces this warning by 
demonstrating that augmentation with FL treatment of po-
tentially potent immunostimulatory cells in a liver allograft 
before its transplantation can lead to an enhanced rejection 
reaction and graft loss in an otherwise spontaneously toler-
ant host. In contrast, FL treatment of the mouse allogeneic 
BM cell recipient, rather than the donor under coverage of 
immunosuppression (tacrolimus) from the time of BM infu-
sion, results in a striking enhancement of chimerism (52). 
Studies such as those reported herein provide compelling 
in vitro immunologic evidence that the timing and circum-
stances of FL administration may determine the balance 
between transplant tolerance and immunity. Precisely how 
this balance is accomplished by the De and other lineages, or 
influenced by growth factors or immunosuppression, remains 
speculative. Further studies of FL and other hematopoietic 
growth factors in the mouse liver transplantation model may 
help elucidate the role of donor-recipient hematopoietic cell 
interactions in determining graft acceptance. Our findings 
also support the prediction that under the appropriate cir-
cumstances, FL-mediated expansion offunctional Des in the 
liver may provide effective strategies to increase immuno-
logic resistance to liver cancer and infectious diseases, such 
as viral hepatitis. It has been obvious since the studies of 
Knight et a1. (53) that "blind" attempts to engineer such 
immunity could lead inadvertently to tolerance, and vice 
versa. 
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